Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
...
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD
- Conditions
- Interventions
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Jinnah Postgraduate Medical Centre
- Target Recruit Count
- 240
- Registration Number
- NCT05942963
- Locations
- 🇵🇰
Medical ICU, Jinnah Postgraduate Medical Centre, Karachi, Sindh, Pakistan
Effects of Metformin Therapy on Pancreatic and Hepatic Fat Content in Patients of Type 2 Diabetes Mellitus
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Diabetes Foundation, India
- Target Recruit Count
- 15
- Registration Number
- NCT05939921
- Locations
- 🇮🇳
Anoop misra, New Delhi, Delhi, India
Towards Precision Medicine for Diabetes in Pregnancy
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Zuyderland Medisch Centrum
- Target Recruit Count
- 103
- Registration Number
- NCT05932251
- Locations
- 🇳🇱
Zuyderland Medisch Centrum, Heerlen, Netherlands
Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- University of Milano Bicocca
- Target Recruit Count
- 25
- Registration Number
- NCT05929495
- Locations
- 🇮🇹
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy
The Impact of Metformin Administration on the Clinical Outcome of Stage IV Colon Cancer
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 70
- Registration Number
- NCT05921942
- Locations
- 🇪🇬
Ain Shams University, Cairo, Egypt
Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes
- Conditions
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Anna Stanhewicz, PhD
- Target Recruit Count
- 30
- Registration Number
- NCT05917587
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 40
- Registration Number
- NCT05910554
Metformin for Fibromyalgia Symptoms (INFORM Trial)
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 72
- Registration Number
- NCT05900466
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
METFORMIN FOR ATRIAL FIBRILLATION
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Arab Contractors Medical Centre
- Target Recruit Count
- 770
- Registration Number
- NCT05878535
- Locations
- 🇪🇬
Arab Contractors Medical Centre, Cairo, Egypt
CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 17
- Registration Number
- NCT05854966
- Locations
- 🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.